INTELIMENSA

Web Summit 2026 · PITCH | Impact Startup | Raising €2.5M Seed

The fastest non-invasive brain-computer interface, giving people who can no longer move or speak their independence back.

~150 bits/min	>98%	6–15×	0
information transfer rate	accuracy · ~10 ms latency	bandwidth of other non-invasive BCIs[1]	surgery or implants · muscle input optional

PROBLEM

- ALS, high spinal cord injury and severe stroke take away speech and movement. Care costs **€80,000–130,000+ per patient per year.**[2]
- Today's aids need residual muscle, voice or eye movement; implants need brain surgery. Only ~2% of people who need a communication aid have one.[3]

SOLUTION

- A patented wearable headset that turns neural intent into real-time control, even as motor function declines. No surgery.
- One device covers many uses: typing, apps, caregiver calls, smart home, wheelchair and robotic-arm control.
- Residual muscle signals can be added for extra speed, so it works alongside patients' existing aids. Usable, never required.

PROOF

- **23+ test sessions** with ALS and tetraplegia users in Paris, Leipzig, Munich and Los Angeles, plus healthy volunteers. TRL 6–7.
- **Patented:** US11157082B2 · EP3843625B1, exclusively licensed, in force to 2039.
- **€1M+ non-dilutive** EU and national funding.
- **Partners:** ARSLA / Institut Charcot (MoU), ALS-mobil, MND Association, University of Manchester.
- **Oct 2026:** robot steered around a room by thought alone.

> *"This is the only BCI interface that worked."*
> ARSLA, France's leading ALS association

MARKET & BUSINESS MODEL

€200B	€0.8B	€78M
TAM · 16.7M people with severe motor impairment	SAM · 67,600 ALS & tetraplegia patients, EU27+UK+US	SOM · 6,500 users, 2029–2033

- **€12,000** one-time device: less than two months of ALS care, and below eye-gaze systems (up to €15,000). **~71% gross margin.**
- Forecast revenue reaches **€33M in 2033**. Beachhead is ALS, then spinal cord injury and stroke.

PITCH

Scan or click for the latest pitch deck

WHY WE WIN

	SURGERY	MUSCLE INPUT	SPEED
Implanted BCIs Neuralink, Synchron, Paradromics, Blackrock Neurotech	Required	Not needed	High
Eye-gaze & switches Tobii Dynavox	None	Required	Medium
Other non-invasive BCIs Cognixion, g.tec mindBEAGLE	None	Not needed	Low
Intelimensa	None	Optional boost	High

ROADMAP

- **2026** Seed round
- **2028** EU MDR class IIa CE mark
- **2029** First EU medical sales
- **2031** US market entry

FOUNDERS

Raul Cristian Mureșan, PhD
CEO · ex-Max Planck group leader, founder of TINS

Danko Nikolić, PhD
CSO · ex-Max Planck group leader

Vasile Vlad Moca, PhD
CTO · ex-Max Planck

Harald Bârzan, PhD
Technology Lead

EXECUTIVE TEAM

Tudor Pasc
Business Development

Sorana Ciura, PhD
Clinical Testing

Veronica Tomescu
Software Development

Irina Patrichi
Marketing

ADVISOR

Randal Schulhauser
MedTech, ~40 years at Medtronic, co-conceived the Reveal implantable cardiac monitor, 50+ patents

THE ASK

€2.5M Seed

24-month runway to CE marking and launch

CE marking 20% · Core team & R&D 19% · Legal, ops & BD 16% · Software 12% · Testing 10% · Pilot devices 8% · Hardware 6% · Buffer 9%

WHAT IT DELIVERS

- EU MDR class IIa CE marking + ISO 13485 quality system
- Clinical evaluation at 3 partner sites (France, Germany, UK)
- 60 pilot devices with patient organisations
- Reimbursement dossiers in 2 launch markets, ready to sell in 2029

Raul Cristian Mureșan, PhD
CEO · +40 745 038 694
raul.muresan@intelimensa.com

Tudor Pasc
Business Development · +40 753 461 740
tudor.pasc@intelimensa.com · intelimensa.com

Impact: SDG 3 | SDG 10 | SDG 8

[1] Compared with published non-invasive BCI benchmarks (arXiv 2308.13232). [2] Berry et al. 2023; Achtert & Kerkemeyer 2021; NSCISC. [3] Tobii Dynavox Q2 2025 results. Market sizes and revenue are company forecasts (base case). Confidential, for investor discussion only.